newsfilter
← Latest News
Earnings Call Transcripts·

Vaxcyte Inc - 1781026 - VAXCYTE INC

  • Financial Performance:

    • The company is in a pre-revenue clinical stage (Scribe Therapeutics); no revenue or profit margins are reported as it operates as a private biotech post-IPO.
    • Capital efficiency is a core metric; the organization executes with significantly less capital than peers, extending runway.
    • The recent IPO funds the development of three lead programs to Phase 1 initial proof-of-concept data.
    • Non-IPO funding includes a grant from the California Institute for Genetic Medicine, which offsets burn rates for the LP(a) and triglyceride programs.
    • Commercial potential is highlighted by the current market size: PCSK9 inhibitors generate ~$5 billion despite only treating ~1% of the eligible population.
  • Guidance and Future Outlook:

    • Lead program (epigenetic silencer for LDL-C) anticipates Phase 1 clinical data release in the first half of next year.
    • Lp(a) lowering program (genome editing) is scheduled to enter the clinic next year; triglyceride lowering program is targeted for entry the year after that.
    • The company aims to transition from a late-symptomatic intervention model to early preventative care, targeting lifelong or multi-year therapeutic effects.
    • Long-term goal is to replicate the cardiovascular protection of natural genetic mutations (e.g., PCSK9 loss-of-function) in the broader population.
    • Commercial strategy focuses on a "one-and-done" curative approach to replace chronic monthly dosing for triglyceride diseases and improve adherence for hyperlipidemia.
  • Business Segments and Product Lines:

    • Platform 1: Elixir (Epigenetic Silencer): Non-damaging gene silencing via chromatin compaction; currently in Phase 1 for PCSK9/LDL-C lowering.
    • Platform 2: X-Editor: Highly evolved CasX-based genome editing tool, evolved over 120+ steps for potency and specificity; used for Lp(a) and triglyceride programs.
    • Cardiovascular Pipeline:
      • LDL-C: Epigenetic silencing targeting PCSK9; non-human primate (NHP) data shows >50% LDL reduction lasting 720 days (2+ years).
      • Lp(a): Genome editing targeting the LPA gene; NHP data shows >95% reduction with no off-target effects on plasminogen.
      • Triglycerides: Genome editing targeting ApoC3; mouse data shows >95% triglyceride reduction and normalization of serum lipids.
    • Partnerships: Active collaboration with Sanofi for in vivo sickle cell and undisclosed genetic medicines (recently expanded to include Elixir technology); partnership with Eli Lilly for neurological/neuromuscular in vivo applications. Both Sanofi and Lilly invested in the recent IPO.
  • Market and Competitive Landscape:

    • Addresses ASCVD (Atherosclerotic Cardiovascular Disease), the leading cause of global mortality, where current therapies suffer from poor patient adherence (70% loss for small molecules, 50% for antibodies within one year).
    • Competitive gap identified in the inability of current RNAi/antibody therapies (e.g., Inclisiran) to maintain long-term efficacy due to dosing frequency and discontinuation rates.
    • Targeting a "best-in-class" profile: >35% LDL-C reduction (potentially >60%) with high patient persistence (potentially lifelong).
    • Differentiation from CRISPR base editors and genome editors lies in the ability to target broad patient populations (adults with elevated risk) rather than rare genetic subsets.
    • Lp(a) market opportunity driven by the recognition that short-term intervention in late life is insufficient; prevention in earlier stages is the emerging standard.
  • Risks and Challenges:

    • Safety/Toxicity: Primary concerns include off-target editing and LNP-related toxicities (ALT/AST/Bilirubin); however, preclinical data indicates tolerability is indistinguishable from saline at doses <1 mg/kg.
    • Durability: While NHP data shows marks lasting 2 years, the long-term stability of epigenetic marks in humans over decades remains a key biological unknown.
    • Market Adoption: Overcoming the entrenched chronic dosing habits of patients and physicians; transitioning from monthly dosing to episodic/cure-based models requires significant market education.
    • Regulatory Path: Although regulators allowed broader inclusion criteria for the LDL-C trial compared to other genetic medicines, long-term safety monitoring for epigenetic modifications will be rigorous.
  • Management Commentary and Tone:

    • Tone is highly confident, emphasizing the unique "first-principles" engineering of their CasX derivative and the non-damaging nature of the Elixir platform.
    • CEO Benjamin Oaks highlights the team's 8+ years of experience and 15 years of personal expertise in molecular engineering as a competitive moat.
    • Management expresses strong conviction that adherence issues with current drugs, not just efficacy, are the primary barrier to reducing global cardiovascular mortality.
    • Emphasis on the "human behavior" solution: creating ultra-long-acting therapies that do not require daily/weekly dosing to succeed.
  • Analyst Questions and Answers:

    • Q (UBS - Ash): Questioned the clinical relevance of >95% reduction in Lp(a) given recent Horizon trial misses.
      • A: Explained that Lp(a) levels remain high throughout life; late-life treatment in the Horizon study captured a small "sliver" of exposure. Future efficacy depends on primary prevention (early intervention) rather than secondary prevention in the elderly.
    • Q (UBS - Ash): Asked about the selection strategy between Lp(a) and Triglyceride programs and the current standard of care for triglycerides.
      • A: Current standards (Ionis/Arrowhead) achieve 60-80% triglyceride reduction but require monthly/quarterly dosing. Scribe views their "one-and-done" genome editing as a superior transition point for patients who have already tolerated RNAi/ASO approaches but need a durable solution to prevent acute pancreatitis.
  • Other Key Points:

    • Preclinical Data Highlights:
      • Elixir molecule is completely cleared from the body in 7 days, but epigenetic effects persist for 720 days (2 years) with no reactivation in NHPs.
      • Human transgenic mouse and primary human hepatocyte models show 2x to 8x higher potency compared to NHPs, suggesting high human efficacy potential.
      • No off-target editing observed in Lp(a) programs even at 10x supersaturation doses across 125+ at-risk sites.
    • Clinical Trial Scope: The Phase 1 trial includes adult patients with elevated LDL and elevated risk, unlike other gene therapies restricted to rare dyslipidemia subsets, expanding the total addressable market.
    • Scientific Innovation: The X-Editor has traversed over 120 steps in sequence space to achieve high specificity, addressing the primary historical barrier to CRISPR therapeutic safety.
Company
VAXCYTE INC
Keywords
VAXCYTE INC